KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $77.1 million.

  • Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.77% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 1.77%. This contributed to the annual value of $76.2 million for FY2024, which is 16.52% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Shares Outstanding (Weighted Average) of $77.1 million as of Q3 2025, which was up 0.49% from $76.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $77.1 million in Q3 2025 and a low of $35.8 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $75.5 million (2024), whereas its average is $71.8 million.
  • Data for Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 51.40% (in 2022) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $51.6 million in 2021, then rose by 21.23% to $62.5 million in 2022, then rose by 4.61% to $65.4 million in 2023, then rose by 16.52% to $76.2 million in 2024, then grew by 1.77% to $77.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $77.1 million in Q3 2025, compared to $76.7 million in Q2 2025 and $76.5 million in Q1 2025.